Everts sprak over flessen met cannabisolie, de inhoud? 10 milliliter..... ha! ha! ha! ha! ha! ha! ha! Eén van de presentatoren, kwal Laseur zo te horen, vroeg Everts niet naar de prijs van zijn product, maar die is niet misselijk: Voor een 'fles' van 10 milliliter met amper nog werkzame stof, vraagt Everts maar liefst € 29,50!! Een 'fles' met zo te zien de sterkst werkzame stof, alweer 10 ml, kost (houdt u vast): € 75,-- ha! ha! ha! ha! ha! ha! ha! Ja, dat is lekker binnenlopen, zal Everts gedacht hebben.
In tempo vertelde Everts dat hij er alles aan doet om binnen de wettelijke grenzen van de Opiumwet te handelen...... Te zot voor woorden, dat dit onder de Opiumwet valt, 'maar goed.......'
Overigens zijn er veel verhalen over de sterke medicinale werking van cannabisolie te vinden op het internet. Men zou er kanker mee tot staan hebben gekregen en in een beperkt aantal gevallen zelfs hebben genezen.
Anti-Media bracht afgelopen zondag een bericht over cannabis, waarin wordt beschreven dat wetenschappers in de VS cannabis eindelijk zien als medicijn, ook tegen een vorm van epilepsie bij kinderen. De FDA houdt het gebruik nog tegen, behalve voor een grote farmaceut, GW Pharmaceuticals, die een eigen gepatenteerde stof Epidiolex heeft ontwikkeld.
De houding van de FDA heeft in de VS de vrees doen ontstaan, dat GW Pharmaceuticals straks de cannabisplant zal patenteren, de cannabisplant is al meer dan drieduizend jaar bekend als een geneeskrachtige plant....... Via de vermaledijde 'vrijhandelsverdragen' CETA en TTIP (dat de EU weer uit de kast wil halen), zal de plant dan ook hier geclaimd worden door GW Pharmaceuticals............
Mainstream Science Finally Accepts Cannabis as Medicine — There’s Just One Problem
May
27, 2017 at 12:52 pm
Written
by Carey
Wedler
(ANTIMEDIA) Mainstream
science is finally starting to accept what
countless parents have known for years: cannabis treats childhood
epilepsy.
According
to a new study published
this week in the New
England Journal of Medicine,
cannabidiol (CBD) has been scientifically demonstrated to treats
Dravet syndrome, a rare seizure disorder. This study is reportedly
the first of its kind to demonstrate CBD’s potential to treat
epilepsy in children in a clinical setting.
“We
now have solid, rigorous scientific evidence that in this specific
syndrome, cannabidiol is effective at reducing seizures,” said
Dr. Orrin Devinsky, a neurologist at New York University Langone
Medical Center and one of the authors of the new study, PBS reported.
For
years, anecdotal evidence has shown CBD’s ability to reduce
seizures. Countless epileptic children have benefitted from the
non-psychoactive substance, as have adults who suffer from conditions
like Parkinson’s
disease and anxiety.
PBS summarized
the study:
“For
the trial, researchers enrolled 120 children from 2 to 18 years old
with Dravet syndrome, a rare genetic form of epilepsy that kills up
to 20 percent of patients by the time they are 20. There are no drugs
approved specifically for Dravet.
“During
the study, the patients stayed on their normal treatment regimen, and
half of them also received cannabidiol while the remainder were given
a placebo. Over a 14-week treatment period, the median number of
convulsive seizures in the cannabidiol group decreased from 12.4 to
5.9 per month; for the placebo group, the number went from 14.9 to
14.1.”
Though
some participants experienced side effects like fatigue and nausea —
and researchers caution more study is needed — the positive effects
of CBD were statistically significant.
According to
Dr. Samuel Berkovic of the University of Melbourne,
who acknowledged the
need for more research, the study represents “the
beginning of solid evidence for the use of cannabinoids in epilepsy.”
While
the findings vindicate the experiences of an increasing number of
people and support mounting research documenting
CBD’s potential, there is just one problem: the study was sponsored
by GW Pharmaceuticals, which backed the study as part of its Phase 3
approval process with the FDA (previous trials had highlighted the
medical benefits, but this installment of the study is more concrete
and has been peer-reviewed).
The
hypocrisy on the part of the Food and Drug Administration is stark;
though the agency has repeatedly refused to
fully acknowledge the medical promise of cannabis, it has allowed
progress for the pharma giant, which brands its version of the
substance Epidiolex.
The
FDA has otherwise denied this potential despite volumes of
studies on cannabis — including CBD — showing the medicinal
benefits not just for epilepsy, but a host of ailments. It claims
more research is necessary, but in previously recommending that
cannabis remain a Schedule I drug, it has helped hinder further
research — except, apparently, by pharmaceutical companies.
By
empowering and elevating GW Pharmaceuticals, the FDA is ultimately
paving the way for a Big Pharma monopoly on the thousands-year-old
plant and, specifically, cannabidiol, which is one of the most
promising cannabinoids for medical use.
Further,
around the country, GW and its American subsidiary, Greenwich
Biosciences, have been hedging
their bets in
state legislatures, lobbying lawmakers to ensure monopolies over
cannabidiol as acceptance of medical marijuana continues to grow and
legalization becomes increasingly inevitable.
Regardless
of the establishment undertones plaguing the new research, however,
the findings are indisputably positive. As PBS further
summarized:
“In
the cannabidiol group, 43 percent of patients had their number of
seizures cut in half or more, compared with 27 percent in the placebo
group. And 5 percent of patients taking cannabidiol saw their
seizures disappear, compared with none in the placebo group.”
Someone
should inform DEA Chief Chuck Rosenberg, who continues to
reiterate his longstanding, false belief that “marijuana
is not medicine.”
He has also said:
“What
really bothers me is the notion that marijuana is also medicinal —
because it’s not.”
He
insinuated it was a “joke.”
Incidentally,
his fact-devoid statements are likely bolstered by
the recommendations of the FDA — the same one currently in the
process of approving GW’s Epidiolex for medical use.
===================================
Klik voor meer berichten n.a.v. het bovenstaande, op één van de labels, die u hieronder terug kan vinden, dit geldt (nog) niet voor de labels: CBD, O. Devinsky, Epidiolex, J. Everts, FDA, C. Rosenberg en Transvaal Apotheek.
Mijn excuus voor de belabberde weergave.
Geen opmerkingen:
Een reactie posten